NCT01160458 · OUTCOME

Safety of IMC-A12 in Patients With Mesothelioma

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy · Source last updated 2018-04-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Date treatment consent signed to date off study, approximately 36 months

What was measured

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.

20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
IMC-A12 Monotherapy in Patients	20

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
IMC-A12 Monotherapy in Patients	20	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.

groups

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Date treatment consent signed to date off study, approximately 36 months

title

Safety of IMC-A12 in Patients With Mesothelioma

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice